Peer Review Committee for Cancer Drug Discovery (CDD)

Areas reviewed

  • Chemical studies dealing with the modification or development of drugs 
  • Preclinical studies involving toxicity and effectiveness
  • Preclinical studies involving the development of drug delivery systems
  • Pharmacological studies
  • Studies involving nuclear magnetic resonance and crystallography on the mechanisms of drug action and on the application of this information to drug design 
  • Studies on the isolation, testing, and synthesis of natural therapeutic agents

Committee Members

Joseph Contessa, MD, PhD, Chair
Yale University
New Haven, CT

Margaret Chu-Moyer, PhD
Amgen, Inc.
Cambridge, MA

Tomasz Cierpicki, PhD
University of Michigan
Ann Arbor, MI

Donna Grande, Stakeholder
Annapolis, MD

M. Kyle Hadden, PhD, Vice-Chair
University of Connecticut
Storrs, CT

Shivaani Kummar, MD, FACP
Stanford University
Palo Alto, CA

Matthew Lazzara, PhD
University of Virginia
Charlottesville, VA

Laura Nathan, Stakeholder
Lafayette, CA

Shannon Stott, PhD
Massachusetts General Hospital
Boston, MA

Regan J. Thomson, PhD
Northwestern University, Evanston Campus
Evanston, IL

Matthew VanBrocklin, PhD
Huntsman Cancer Institute, University of Utah
Salt Lake City, UT

David N. Wald, MD, PhD
Case Western Reserve University
Cleveland, OH